Smallpox

SBIR grant awarded to develop anti-smallpox therapeutics

Published in Vaccine Weekly, October 8th, 2003

Aphios Corporation has been awarded a phase I Small Business Innovative Research (SBIR) grant for the "Development of Novel Anti-Smallpox Therapeutics from Marine Microorganisms," from the National Center for Complementary and Alternative Medicine (NCCAM) of the U.S. National Institutes of Health (NIH).

Smallpox infection is characterized by a high fever and rash; the mortality rate is very high, approximately 30%. Person to person infection usually occurs by the transfer of aerosols or fluid droplets. The vast vaccination effort between 1967 and 1972 led to the worldwide eradication of Smallpox in 1977.

Currently, viral stocks of Smallpox are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-10-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry